|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative显示文摘 | Sypsa VA Mimidis K Tassopoulos NC | 2005 | Hepatology2005，42，1： | 1 |
| 2 | Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir显示文摘 | George V. Papatheodoridis George N. Dalekos Cihan Yurdaydin Maria Buti John Goulis Pauline Arends Vana Sypsa Spilios Manolakopoulos Giampaolo Mangia Nikolaos Gatselis Onur Kesk?n Savvoula Savvidou Bettina E. Hansen Christos Papaioannou Kostantinos Galanis | 2014 | Journal of Hepatology2014，，： | 1 |
| 3 | Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load显示文摘 | Katsoulidou A Moschidis Z Sypsa V | 2007 | Vox Sang2007，92，1： | 1 |
| 4 | A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative 显示文摘 | Sypsa VA Mimidis K Tassopoulos NC | 2005 | Hepatology2005，42，1： | 1 |
| 5 | A survey of bloodborne viruses and associated risk behaviours in Greek prisons显示文摘 | M. Malliori V. Sypsa M. Psichogiou G. Touloumi A. Skoutelis N. Tassopoulos A. Hatzakis C. Stefanis | 1998 | Addiction1998，，2： | 1 |
| 6 | Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load显示文摘 | Katsoulidou A Moschidis Z Sypsa V | 2007 | Vox Sang2007，92，1： | 1 |
| 7 | School closure is currently the main strategy to mitigate influenza A( H1NI ) : A modeling study显示文摘 | SYPSA V HATZAKIS A | 2009 | Eurosurveillance2009，14，24： | 1 |
| 8 | A viral kinetic study using pegylated interferon alfa-2b and/or lamlvudine in patients with chronic hepatitis B/HBeAg negative 显示文摘 | Sypsa VA Mimidis K Tassopoulos NC | 2005 | Hepatology2005，42，1： | 1 |
| 9 | Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals显示文摘BACKGROUND Hepatitis C virus(HCV) is a leading cause of worldwide liver-related morbidity and mortality. The World Health Organization released an integrated strategy targeting HCV-elimination by 2030. This study aims to estimate the required interventions to achieve elimination using updated information for direct-acting antiviral(DAA) treatment coverage, to compute the total costs(including indirect/societal costs) of the strategy and to identify whether the elimination strategy is cost-effective/cost-saving in Greece.AIM To estimate the required interventions and subsequent costs to achieve HCV elimination in Greece.METHODS A previously validated mathematical model was adapted to the Greek HCVinfected population to compare the outcomes of DAA treatment without the additional implementation of awareness or screening campaigns versus an HCV elimination strategy, which includes a sufficient number of treated patients. We estimated the total costs(direct and indirect costs), the disability-adjusted life years and the incremental cost-effectiveness ratio using two different price scenarios.RESULTS Without the implementation of awareness or screening campaigns,approximately 20000 patients would be diagnosed and treated with DAAs by2030. This strategy would result in a 19.6% increase in HCV-related mortality in2030 compared to 2015. To achieve the elimination goal, 90000 patients need to be treated by 2030. Under the elimination scenario, viremic cases would decrease by78.8% in 2030 compared to 2015. The cumulative direct costs to eliminate the disease would range from 2.1-2.3 billion euros(€) by 2030, while the indirect costs would be €1.1 billion. The total elimination cost in Greece would range from €3.2-3.4 billion by 2030. The cost per averted disability-adjusted life year is estimated between €10100 and €13380, indicating that the elimination strategy is very costeffective. Furthermore, HCV elimination strategy would save €560-895 million by2035.CONCLUSION Without large screening programs, elimination of HCV cannot be achieved. The HCV elimination strategy is feasible and cost-saving despite the uncertainty of the future cost of DAAs in Greece. | Ilias Gountas Vana Sypsa George Papatheodoridis Kyriakos Souliotis Kostas Athanasakis Homie Razavi Angelos Hatzakis | 2019 | World Journal of Gastroenterology2019，25，11： | 1 |
| 10 | School closure is currently the main strategy to mitigate influenza A(H1N1)v: A Modeling study 显示文摘 | Sypsa V Hatzakis A | 2009 | Eum SurveiU2009，14，19： | 1 |
| 11 | Public perceptions in relation to intention to receive pandemic influenza vaccination in a random population sample: evidence from a cross-sectional tele- phone survey 显示文摘 | Sypsa V Livanios T Psichogiou M | 2009 | EuroSurveill2009，14，49： | 1 |
| 12 | Enhanced HIV1 surveillance using molecular epidemiology to study and monitor HIV1 outbreaks among intravenous drug users (IDUs)in Athens and Bucharest显示文摘 | Paraskevis D Paraschiv S Sypsa V | 2015 | Infect Genet Evol2015，35，4： | 1 |
| 13 | A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative显示文摘 | SYPSA VA MIMIDIS K TASSOPOULOS NC | 2005 | Hepatology2005，42，： | 1 |
| 14 | Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey显示文摘 | G. Papatheodoridis V. Sypsa M. Kantzanou I. Nikolakopoulos A. Hatzakis | 2015 | J Viral Hepat2015，，4： | 1 |
| 15 | A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative显示文摘 | Sypsa V A Mimidis K Tassopoulos N C | 2005 | Hepatology2005，42，1： | 1 |
| 16 | School closure is currently the main strategy to mitigate influenza A( H1N1 ) v: a modeling study显示文摘 | SYPSA V HATZAKIS A | 2009 | Euro Surveill2009，14，24： | 1 |
| 17 | Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients显示文摘 | Sypsa V Psichogiou M Katsoulidou A | 2005 | Am J Kidney Dis2005，45，2： | 1 |
| 18 | Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments显示文摘 | Sypsa V Touloumi G Papatheodoridis GV | 2005 | J Viral Hepat2005，12，5： | 1 |
| 19 | The course of hepati- tis C virus infection in pretransplantation anti - hepatitis C virus - negative renal transplant recipients: a retrospective follow - up study 显示文摘 | Delladetsima I Psichogiou M Sypsa V | 2006 | Am J Kidney Dis2006，47，2： | 1 |
| 20 | A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative显示文摘 | Sypsa VA Mimidis K Tassopoulos NC | 2005 | Hepatology2005，42，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员